GlaxoSmithKline (CAI:BIOC) Total Assets: E£1,881 Mil (As of Sep. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is GlaxoSmithKline Total Assets?

GlaxoSmithKline CAI:BIOC -6.97% Total Assets is E£1,881 Mil as of Sep. 2016.

GlaxoSmithKline's Total Assets for the quarter that ended in Sep. 2016 was E£1,881 Mil.

Total Assets is connected with ROA %. GlaxoSmithKline's annualized ROA % for the quarter that ended in Sep. 2016 was 22.44%. Total Assets is also linked to Revenue through Asset Turnover. GlaxoSmithKline's Asset Turnover for the quarter that ended in Sep. 2016 was 0.14.

GlaxoSmithKline  (CAI:BIOC) Total Assets Explanation

Total Assets is connected with ROA %.

GlaxoSmithKline's annualized ROA % for the quarter that ended in Sep. 2016 is

ROA %=Net Income (Q: Sep. 2016 )/( (Total Assets (Q: Jun. 2016 )+Total Assets (Q: Sep. 2016 ))/ count )
=414.96/( (1817.523+1880.786)/ 2 )
=414.96/1849.1545
=22.44 %

Note: The Net Income data used here is four times the quarterly (Sep. 2016) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

GlaxoSmithKline's Asset Turnover for the quarter that ended in Sep. 2016 is

Asset Turnover
=Revenue (Q: Sep. 2016 )/( (Total Assets (Q: Jun. 2016 )+Total Assets (Q: Sep. 2016 ))/ count )
=267.715/( (1817.523+1880.786)/ 2 )
=267.715/1849.1545
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

GlaxoSmithKline Total Assets Related Terms

GlaxoSmithKline Total Assets Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Total Assets Chart

GlaxoSmithKline Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Total Assets
1,193.92 1,382.04 1,465.11 1,766.51

GlaxoSmithKline Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,703.13 1,766.51 1,854.72 1,817.52 1,880.79

GlaxoSmithKline Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

GlaxoSmithKline's Total Assets for the fiscal year that ended in Dec. 2015 is calculated as

Total Assets=Total Equity (A: Dec. 2015 )+Total Liabilities (A: Dec. 2015 )
=1002.826+763.685
=1,767

GlaxoSmithKline's Total Assets for the quarter that ended in Sep. 2016 is calculated as

Total Assets=Total Equity (Q: Sep. 2016 )+Total Liabilities (Q: Sep. 2016 )
=1071.972+808.814
=1,881

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of E£1,881 Mil mean?
GlaxoSmithKline (CAI:BIOC) has a Total Assets of E£1,881 Mil as of Sep. 2016. The total amount of assets as recorded on a company's balance sheet. View historical data on GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's Total Assets too high?
GlaxoSmithKline's current Total Assets is E£1,881 Mil.
How does GlaxoSmithKline's Total Assets compare to PRPH?
GlaxoSmithKline's Total Assets of E£1,881 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on GlaxoSmithKline and its competitors. GlaxoSmithKline's current Total Assets is E£1,881 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Total Assets of E£1,881 Mil. The current Total Assets is E£1,881 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Total Assets is E£1,881 Mil as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlaxoSmithKline Business Description

Address Boomerang Building, No 46, Block (J) First Section City Centre, Town Centre, Second floor, Fifth District - New Cairo, Cairo, EGY, 11835
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.